InvestorsHub Logo
Post# of 252504
Next 10
Followers 38
Posts 5652
Boards Moderated 0
Alias Born 11/09/2003

Re: xavierprivas post# 236754

Friday, 01/15/2021 1:36:59 PM

Friday, January 15, 2021 1:36:59 PM

Post# of 252504
re: CRDF

xavier,

The ORR keeps going down to 42%. In the past folfox chemotherapy has achieved 50% in KRAS CRC
but eventually failed later.



Can you elaborate on the 50% figure that you cite? Is that in 2nd line? where did you get that figure from?

From the PR

- Of the 12 Phase 1b patients evaluable for efficacy as of the ASCO-GI data cut-off date (November 1, 2020), 5 (42%) achieved a partial response (PR) and 8 (67%) have shown a durable response ranging from 6.1 to 13.7 months

- Since the ASCO-GI data cut-off date, 2 additional Phase 1b patients have had their initial 8-week scan showing stable disease (SD) and both remain on treatment to-date



These last two patients may convert to PR.

- In the Expanded Access Program (EAP), 6 (66%) of the initial 9 patients treated have shown tumor shrinkage and remain on treatment to-date with durable responses lasting an average of 6 months; 5 different KRAS mutation subtypes are represented (G12A, G12C, G12V, G13D, A146T); all patients had received prior treatment with FOLFIRI



It's not perfectly clear, but I assume that the patients that have shown tumor shrinkage in the EAP are all PR's.


The market expects more. Well this is a known hazard of biotech investing where further trial result disappoints.



Agreed.

All in all, I'd say this was an overreaction to the data.


Bladerunner

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.